4.6 Article

Work productivity in rhinitis using cell phones: The MASK pilot study

期刊

ALLERGY
卷 72, 期 10, 页码 1475-1484

出版社

WILEY
DOI: 10.1111/all.13177

关键词

Allergic Rhinitis and its Impact on Asthma; app; rhinitis; work productivity; WPAIA:AS

资金

  1. AstraZeneca
  2. AbbVie
  3. ALK
  4. Almirall
  5. Astellas
  6. Bayer Health Care
  7. Bencard
  8. Berlin Chemie
  9. FAES
  10. HAL
  11. Henkel
  12. Kryolan
  13. Leti
  14. L'Oreal
  15. Meda
  16. Menarini
  17. Merck
  18. MSD
  19. Novartis
  20. Pfizer
  21. Sanofi
  22. Stallergenes
  23. Takeda
  24. Teva
  25. UCB
  26. Asthma UK [MRC-AsthmaUKCentre, MRC-Asthma UK Centre] Funding Source: researchfish
  27. Medical Research Council [G1000758B, G1000758] Funding Source: researchfish

向作者/读者索取更多资源

Allergic rhinitis often impairs social life and performance. The aim of this cross-sectional study was to use cell phone data to assess the impact on work productivity of uncontrolled rhinitis assessed by visual analogue scale (VAS). A mobile phone app (Allergy Diary, Google Play Store and Apple App Store) collects data from daily visual analogue scales (VAS) for overall allergic symptoms (VAS-global measured), nasal (VAS-nasal), ocular (VAS-ocular) and asthma symptoms (VAS-asthma) as well as work (VAS-work). A combined nasal-ocular score is calculated. The Allergy Diary is available in 21 countries. The app includes the Work Productivity and Activity Impairment Allergic Specific Questionnaire (WPAI: AS) in six EU countries. All consecutive users who completed the VAS-work from 1 June to 31 October 2016 were included in the study. A total of 1136 users filled in 5818 days of VAS-work. Symptoms of allergic rhinitis were controlled (VAS-global <20) in approximately 60% of the days. In users with uncontrolled rhinitis, approximately 90% had some work impairment and over 50% had severe work impairment (VAS-work >50). There was a significant correlation between VAS-global calculated and VAS-work (Rho=0.83, P<0.00001, Spearman's rank test). In 144 users, there was a significant correlation between VAS-work and WPAI: AS (Rho=0.53, P<0.0001). This pilot study provides not only proof-of-concept data on the work impairment collected with the app but also data on the app itself, especially the distribution of responses for the VAS. This supports the interpretation that persons with rhinitis report both the presence and the absence of symptoms.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据